Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite E
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol Management Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks
View HTML
Toggle Summary Amarin to Present at the Jefferies 2018 London Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations
Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and
View HTML
Toggle Summary Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association
Webcast to Commence at 7:15 p.m. CT / 8:15 p.m. ET , Saturday, November 10, 2018 BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve
View HTML
Toggle Summary Amarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members
View HTML
Toggle Summary Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 19, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto II Designated Activity Company, a designated activity company with limited liability incorporated under the laws
View HTML
Toggle Summary Amarin to Present at the Cantor Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint
REDUCE-IT Is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific to Pure EPA Vascepa at 4 Grams Daily Conference Call Scheduled for Today, Monday, September 24, 2018 at
View HTML
Toggle Summary REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association
Topline Results of the REDUCE-IT Study Anticipated Before End of September 2018 BEDMINSTER, N.J. and DUBLIN, Ireland , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve
View HTML
Toggle Summary Amarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results
REDUCE-IT is the First Study of Any Therapy to Prospectively Enroll and Evaluate Risk Reduction for Cardiovascular Events in Statin-Treated Patients with Elevated Triglyceride Levels and Other Cardiovascular Risk Factors REDUCE-IT Study Remains On-Track for Report of Top-Line Results Before the End
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation